

Current report №112 /2024

Dated October 4, 2024

NOTIFICATION

“Sopharma” AD (the Company) notifies, that following its growth strategy and its goal of becoming a stronger regional player, the Company initiates a transaction for acquisition of a pharmaceutical product portfolio consisting of both CHC and prescription products in the following therapeutic areas: Sex hormones and modulators of the genital system, Urologicals and Antivirals for systemic use. The acquisition totals 68 marketing authorizations with 14 well-known brands in 10 of the traditional markets of the Company.

The transaction will take place in several stages and its closing is subject to certain condition precedents. The acquisition will be financed with own funds and through an investment loan from a financial institution.

Ognian Donev